

radmagazine
 FOR MEDICAL IMAGING AND RADIOTHERAPY PROFESSIONALS

Keeping you
 up-to-date
 every day



radmagazine.com



@radmagazine



@radmagazine



@RADMagazine



@RADMagazineuk

ADVERTISING AND EDITORIAL COPY:

Suite 2, Lynderswood Court,
 London Road, Black Notley,
 Braintree, CM77 8QN

TELEPHONE:
 (01371) 812960

MANAGING DIRECTOR/SALES:
 Mechel Rees
 mechel@radmagazine.com

OPERATIONS:
 Katherine Powell
 katherine@radmagazine.com

ADMINISTRATION:
 Sue Wallbank
 sue@radmagazine.com

EDITORIAL SERVICES:
 Stansted News Limited

RAD Magazine is published monthly by Kingsmoor Publications Limited, Suite 2, Lynderswood Court, London, Road, Black Notley, Braintree, CM77 8QN. Production by Stansted News Limited, Bishop's Stortford, and printed by Hardings Print Solutions Limited.


radmagazine is a registered Community Trade Mark covering the European Union. The trademark is also registered in various other jurisdictions. For a full list of jurisdictions visit radmagazine.com

Plug and play in-wall consoles expand portfolio for the operating room

Barco has expanded its hardware portfolio with three in-wall consoles that have built-in Nexxis functionality, meaning they can be integrated easily within new and existing Nexxis systems. The series also makes it possible to attach mobile devices, such as C-arms. All three consoles offer a Nexxis button that can be programmed for specific tasks, for example to start or stop recordings, to take snapshots or to change video layouts.

The MDMX series offers a choice between three displays, each with a black anti-reflective glass front cover that allows easy cleaning and disinfecting. The options are the MDMX-22400 GNTB 24" full HD console, the MDMX-25500 GNNB 55" 4K console and the MDMX-22449 GNTB combined display configuration of a 24" full HD and a 49" 4K display.

The MDMX-22400 GNTB and MDMX-25500 GNNB can be combined next to each other in a dual set-up. Consoles come with optional trackpad, mouse and foldable IP68 keyboard, available in multiple languages.



OncoSil reduction of tumour. Picture courtesy Dr Berry Allen 2021.

The London Clinic introduces OncoSil treatment for pancreatic cancer

Independent hospital and charity The London Clinic says it is the first independent hospital in the UK to employ OncoSil, said to be a breakthrough new treatment for pancreatic cancer.

OncoSil is a single use brachytherapy device that delivers a pre-determined dose of beta radiation directly into cancerous tissue. It is used in combination with chemotherapy to treat patients with locally advanced pancreatic cancer.

Pancreatic cancer occurs when abnormal cells in the pancreas grow out of control, with symptoms varying according to the tumour type and location. People often do not show symptoms in the earlier stages of the disease and so it is difficult to detect. This nuclear medicine therapy offers a new option for the treatment of locally advanced pancreatic cancer where the tumour is unresectable.

The beta particles emitted by OncoSil cause damage to cancer cell DNA, which renders them incapable of further cell division and can ultimately shrink the tumour mass.

OncoSil has been shown in clinical studies to increase overall survival and lead to downstaging, allowing patients to undergo surgery to remove their tumours. This surgery statistically improves the five-year survival rate from around seven per cent to more than 20 per cent.

OncoSil implantation is an outpatient procedure that takes around 60 minutes. Dr Zarni Win is consultant radiologist and nuclear medicine physician at the clinic in Harley Street. He said: "I am particularly excited about this new therapy, as it now offers a much higher chance for pancreatic cancer patients with locally advanced disease to undergo curative surgery following OncoSil therapy, compared to a pessimistic outcome with conventional treatment."

During the PanCO clinical study, which had participating sites in Australia, the UK and Belgium, a total of 50 subjects were enrolled with 42 subjects successfully implanted with the OncoSil device. The London Clinic says it performed the largest number of implantations in the UK and EU during this study and will be the first centre in the UK to treat patients using the technology this year.

"I am delighted that The London Clinic will be the first institution in the UK to routinely offer patients with unresectable locally advanced pancreatic cancer treatment with the OncoSil device," said ceo and managing director, OncoSil medical president, EMEA Nigel Lange. "This provides patients and their clinicians with an encouraging new approach and hope, in a disease where there has been little advancement for decades."



Björn Segall tests a GE-4c-RS ultrasound probe on ProbeHunter.

Fifty OEM ultrasound probe adapters are now available from ProbeHunter

ProbeHunter, a company that specialises in the dynamic testing and performance validation of ultrasound probes, has released an adapter to the Mindray DC-8 series.

ProbeHunter and BBS Medical ceo Björn Segall explained: "This means that we now can test all leading OEM's ultrasound probes such as GE Healthcare, Philips, Siemens Healthineers, Samsung, Mindray and more, independent from the system on ProbeHunter."

"With 50 different multi-brand adapters in the portfolio, we can offer hospitals and anyone dealing

with or servicing ultrasound probes the ultimate tool for patient safety."

ProbeHunter is a real-time QA testing device and is designed for patient safety; the user can achieve a quick 'go or no go' before using an ultrasound probe on a patient.

Segall added: "It is now easier than ever to get a ProbeHunter system; the Swedish Government supports export business and offers a capital credit guarantee during the pandemic. It means, in general, that it is possible to have a ProbeHunter system today and pay later."

West Suffolk Hospital offers adaptable breast ultrasound

Continued from front page

"The remote support and user-friendly interface have helped the team to rapidly familiarise itself with the Acuson Sequoia, and patient-focused features like the gel warmer are a welcome addition."

Before COVID-19, the service saw around 13,000 women every year but, like many breast screening services, the trust has seen a drop in attendance. According to Breast Cancer Now, nearly one million women across the UK have missed potentially lifesaving NHS breast screening due to the pandemic.

The Acuson Sequoia supports accurate, reproducible diagnoses. It uses BioAcoustic technology that adapts to the patient's size and characteristics in order to provide a bespoke approach to scanning. The sensitive single crystal transducers provide optimal axial resolution and breast-specific adaptations, facilitating accurate differentiation, clear needle visualisation and reliable measurements of depth for biopsy and fine needle aspiration.

"We are pleased to see the Acuson Sequoia supporting staff and patients at West Suffolk NHS Foundation Trust's breast department," said Siemens Healthineers GB&I ultrasound business lead Harshal Vadera.

"The system will help reduce the effects of ultrasound variability between users, patients and technology, and will help deliver effective clinical insights to medical practitioners."